首页> 美国卫生研究院文献>Journal of Aerosol Medicine and Pulmonary Drug Delivery >Bridging the Gap Between Science and Clinical Efficacy: Physiology Imaging and Modeling of Aerosols in the Lung
【2h】

Bridging the Gap Between Science and Clinical Efficacy: Physiology Imaging and Modeling of Aerosols in the Lung

机译:弥合科学与临床功效之间的鸿沟:肺部气溶胶的生理学成像和建模

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Development of a new drug for the treatment of lung disease is a complex and time consuming process involving numerous disciplines of basic and applied sciences. During the 2015 Congress of the International Society for Aerosols in Medicine, a group of experts including aerosol scientists, physiologists, modelers, imagers, and clinicians participated in a workshop aiming at bridging the gap between basic research and clinical efficacy of inhaled drugs. This publication summarizes the current consensus on the topic. It begins with a short description of basic concepts of aerosol transport and a discussion on targeting strategies of inhaled aerosols to the lungs. It is followed by a description of both computational and biological lung models, and the use of imaging techniques to determine aerosol deposition distribution (ADD) in the lung. Finally, the importance of ADD to clinical efficacy is discussed. Several gaps were identified between basic science and clinical efficacy. One gap between scientific research aimed at predicting, controlling, and measuring ADD and the clinical use of inhaled aerosols is the considerable challenge of obtaining, in a single study, accurate information describing the optimal lung regions to be targeted, the effectiveness of targeting determined from ADD, and some measure of the drug's effectiveness. Other identified gaps were the language and methodology barriers that exist among disciplines, along with the significant regulatory hurdles that need to be overcome for novel drugs and/or therapies to reach the marketplace and benefit the patient. Despite these gaps, much progress has been made in recent years to improve clinical efficacy of inhaled drugs. Also, the recent efforts by many funding agencies and industry to support multidisciplinary networks including basic science researchers, R&D scientists, and clinicians will go a long way to further reduce the gap between science and clinical efficacy.
机译:开发用于治疗肺部疾病的新药物是一个复杂且耗时的过程,涉及许多基础科学和应用科学领域。在2015年国际气雾剂医学学会大会上,包括气溶胶科学家,生理学家,建模师,成像师和临床医生在内的一组专家参加了一个研讨会,旨在弥合基础研究与吸入药物的临床疗效之间的差距。该出版物总结了当前对该主题的共识。首先简要介绍了气雾运输的基本概念,并讨论了将气雾吸入肺的靶向策略。接下来是对计算模型和生物学模型的描述,并介绍了使用成像技术确定肺中气溶胶沉积分布(ADD)的方法。最后,讨论了ADD对临床疗效的重要性。在基础科学和临床疗效之间发现了一些差距。旨在预测,控制和测量ADD的科学研究与吸入气雾剂的临床用途之间的一个鸿沟是一项艰巨的挑战,那就是在一项研究中获得准确的信息来描述要靶向的最佳肺区域,并从中确定靶向的有效性。添加,并衡量该药物的有效性。其他已确定的差距是各学科之间存在的语言和方法障碍,以及为使新药和/或疗法进入市场并使患者受益而需要克服的重大监管障碍。尽管存在这些差距,但近年来在改善吸入药物的临床疗效方面已取得了很大进展。此外,许多资助机构和行业最近为支持包括基础科学研究人员,研发科学家和临床医生在内的多学科网络所做的努力将大大缩短科学与临床功效之间的差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号